Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio

Core Viewpoint - Atossa Therapeutics has been granted a new patent for (Z)-endoxifen formulations, enhancing its intellectual property portfolio and supporting its mission to advance breast cancer treatment [1][2][3] Group 1: Patent and Intellectual Property - The newly granted patent (U.S. Patent No. 12,281,056) includes 58 claims related to (Z)-endoxifen formulations, focusing on purity, stability, and therapeutic methods [2] - Atossa's patent estate now encompasses over 200 claims related to (Z)-endoxifen formulations and their clinical applications, reinforcing the company's leadership in targeted therapies for hormone receptor-positive breast cancer [3] Group 2: Product Development and Efficacy - (Z)-endoxifen is a potent Selective Estrogen Receptor Modulator (SERM) that may cause estrogen receptor degradation and has shown efficacy in patients resistant to other hormonal treatments [4] - The company is developing an oral formulation of (Z)-endoxifen designed to bypass the stomach, which converts a significant portion of the drug to an inactive form [5] - Clinical studies indicate that (Z)-endoxifen is well tolerated in women with and without breast cancer, and it is being studied for both treatment and prevention of breast cancer, including a program for metastatic breast cancer [5] Group 3: Company Mission and Vision - Atossa is dedicated to transforming breast cancer treatment through innovative science and patient-focused solutions, aiming to improve the lives of millions of women while generating substantial value for shareholders [3][6]